Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Japan’s Itochu Biologic Subsidiary To Launch First Drug In Taiwan

This article was originally published in PharmAsia News

Executive Summary

Japanese major trading house Itochu's bioventure subsidiary, Tokyo-based Solasia Pharma K.K., plans to launch its first drug to the Taiwanese market within the year. The drug, Sancuso (transdermal granisetron) patch is for chemotherapy-induced nausea and vomiting. Solasia also is preparing to launch the drug in China and other Asian markets. Compared to current oral therapy, the Sancuso patch allows patients with swallowing difficulties to use it. The company aims for ¥8 billion in annual sales by 2015. (Click here for more - Japanese language



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts